Status:
COMPLETED
A Study To Investigate Whether PF-04457845 Is Effective In Treating Pain, Is Safe And Tolerable In Patients With Osteoarthritis Of The Knee
Lead Sponsor:
Pfizer
Conditions:
Osteoarthritis, Knee
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
Inactivation of the FAAH (Fatty Acid Amide Hydrolase) enzyme has been shown to relieve pain and inflammation in animal studies. PF-04457845 has been shown to inactivate the FAAH enzyme in animals and ...
Eligibility Criteria
Inclusion
- Subjects must have a diagnosis of Osteoarthritis (OA) of the knee confirmed by X-ray
- Subjects must be willing and able to stop all current pain therapy for the duration of study. (Limited and specific pain therapy will be available throughout the study)
- Subjects can be male or female between the ages of 18 and 75 years inclusive, but female subjects must not be able become pregnant
Exclusion
- Subjects must not have any condition or medical history that might interfere with their ability to complete the study assessments
Key Trial Info
Start Date :
November 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2010
Estimated Enrollment :
76 Patients enrolled
Trial Details
Trial ID
NCT00981357
Start Date
November 1 2009
End Date
May 1 2010
Last Update
September 19 2017
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Arthritis & Rheumatic Care Center
Miami, Florida, United States, 33143
2
Miami Research Associates
Miami, Florida, United States, 33143
3
Vince and Associates Clinical Research
Overland Park, Kansas, United States, 66211
4
Vince and Associates Clinical Research
Overland Park, Kansas, United States, 66212